You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Trelegy Ellipta?

Trelegy Ellipta is used to treat chronic obstructive pulmonary disease (COPD) in adults. COPD is a long term condition characterised by breathing difficulties that slowly get worse.

In COPD the muscles around the airways tighten, making breathing difficult. This medicine widens these muscles in the lungs, reducing the swelling and irritation in the small air passages and making it easier for air to get in and out of the lungs. When used regularly, it can help to control your breathing difficulties and reduce the effects of COPD on your everyday life.

Trelegy Ellipta contains three active substances called fluticasone furoate, umeclidinium bromide and vilanterol (as trifenatate). Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. Umeclidinium bromide and vilanterol belong to a group of medicines called bronchodilators. 1-2

Patient information

Patient information

This information is specifically for patients that have been prescribed Trelegy Ellipta by a UK healthcare professional

I am a Trelegy COPD patient

COPD information

COPD information

Here you can find links to professional organisations and other useful websites for information about chronic obstructive pulmonary disease (COPD).

Read more

Safety information

For safety information on Trelegy Ellipta including information on who is suitable for a Trelegy prescription, please see the Trelegy Ellipta patient information leaflet linked below

References:

  1. Trelegy Ellipta patient information leaflet GB
  2. Trelegy Ellipta patient information leaflet NI

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/.
By reporting side effects you can help provide more information on the safety of this medicine.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies